{
    "root": "8b71204c-39a3-472e-a755-b00e6baf26f9",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Pravastatin Sodium",
    "value": "20250501",
    "ingredients": [
        {
            "name": "PRAVASTATIN SODIUM",
            "code": "3M8608UQ61"
        },
        {
            "name": "SAND",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "HYDROXYPROPYL METHYLCELLULOSE",
            "code": "3NXW29V3WO"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "METHYLGLUCAMINE",
            "code": "6HG8UB2MUY"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "ZEA MAYS (CORN) STARCH",
            "code": "O8232NY3SJ"
        },
        {
            "name": "YELLOW 10",
            "code": "35SW5USQ3G"
        },
        {
            "name": "BLUE 1",
            "code": "H3R47K3TBD"
        }
    ],
    "indications": "Pravastatin sodium tablets are indicated:\n                           \n                              1.To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD).\n                           \n                              2.To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD.\n                           \n                              3.As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia.\n                           \n                              4.As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH).\n                           \n                              5.As an adjunct to diet for the treatment of adults with:\n                                 \n                                    •Primary dysbetalipoproteinemia.\n                                 \n                                    •Hypertriglyceridemia.",
    "contraindications": "• Take orally once daily at any time of the day, with or without food ( 2.1 ). • For patients that require a high-intensity statin or are unable to achieve their LDL-C goal receiving pravastatin sodium tablets 80 mg daily, prescribe alternative LDL-C-lowering treatment ( 2.1 ). • Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating pravastatin sodium, and adjust the dosage if necessary ( 2.1 ). • Adults: recommended starting dosage is pravastatin sodium tablets 40 mg to 80 mg once daily. ( 2.2 ) • Pediatric Patients ( 2.3 ): • aged 8 to 13 years, the recommended dosage is 20 mg once daily. • aged 14 to 18 years, the recommended starting dosage is 40 mg once daily. • Severe renal impairment: recommended starting dosage is pravastatin sodium 10 mg once daily. Recommended maximum pravastatin sodium tablets dosage is 40 mg once daily. ( 2.4 ) • See full prescribing information for dosage modifications due to drug interactions ( 2.5 , 7 ).",
    "warningsAndPrecautions": "Product:    50090-1533\n                  NDC:    50090-1533-0   30 TABLET in a BOTTLE\n                  NDC:    50090-1533-1   90 TABLET in a BOTTLE\n                  Product:    50090-1594\n                  NDC:    50090-1594-0   90 TABLET in a BOTTLE\n                  NDC:    50090-1594-1   30 TABLET in a BOTTLE",
    "adverseReactions": "Acute liver failure or decompensated cirrhosis [see Warnings and Precautions (\n                     \n                     \n                        5.3\n                        )\n                     \n                     ].\n                     \n                  \n                  \n                     Hypersensitivity to any pravastatin or any excipients in pravastatin sodium tablets."
}